ATAD1 and malaria: For example, the malaria vaccine combination B, designed as a three-component blood-stage product targeting the merozoite surface proteins MSP-1 (K1 parasite line) and MSP-2 (3D7), and the ring-infected erythrocyte surface antigen (RESA) was efficient against homologous parasites harboring the 3D7 allelic family of MSP-2, but failed to protect against those containing the FC27 allelic family, and was even associated with an increased rate of morbidity [6].